Chronic kidney disease (CKD) is an emerging problem in patients with treated HIV.
Antiretroviral therapy associated renal dysfunction has been predominantly described in terms
of reduced glomerular filtration (eGFR). Proteinuria is a key component of CKD and may occur
in the absence of significant reductions in eGFR. This substudy is an exploration of changes
in urinary protein excretion in a randomised, open-label study to evaluate the efficacy and
safety of MVC as a switch for either nucleoside or nucleotide analogue reverse transcriptase
inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with
stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of
combination antiretroviral therapy (cART).